At Sygnature Discovery we are committed to adding value to our client’s programs by providing relevant and innovative solutions to their discovery programs. Our experienced scientists regularly engage with the drug discovery community to share our recent advances, expert opinion and updates on our successful collaborations, helping Sygnature to remain at the leading edge of scientific advances. Download our most recent scientific presentations here.
Building a modern screening library and infrastructure
Many organisations have inherited a legacy library and screening infrastructure which in some cases has been tweaked to reflect modern thinking on lead-like properties and toxicity liabilities or improved informatics. At Sygnature we have...
FIND OUT MOREEnabling success in lead identification
A crucial part of identifying novel leads is the diversity and suitability of the molecules to be screened which in turn will determine the likelihood of obtaining viable chemical starting points for new projects....
FIND OUT MOREBetter trials demand better oncology drugs…
…but how do we deliver them? The ethos of cancer drug discovery is changing and in the recent Phase 1 clinical trial meeting in Manchester, we discussed the demands that these changes place on...
FIND OUT MOREA Breath of Fresh Air: Delivering Novel Respiratory Syncytial Virus (RSV) Inhibitors
Abstract Pulmocide Ltd., a VC-funded biotechnology company, was founded to discover more effective and safer inhaled treatments for serious viral and fungal infections of the respiratory tract. Human respiratory syncytial virus (hRSV) is the...
FIND OUT MORESmarter IDO inhibitor profiling using biophysical, biochemical and cellular target engagement approaches
Abstract In small molecule drug discovery for intracellular enzyme inhibitors, it is essential to have an efficient and informative hit profiling strategy in place that ideally measures target engagement in situ. Using inhibitors of...
FIND OUT MORE